Emerald Health Pharmaceuticals Announces Final Closing Date For its Regulation A+ Offering
09. März 2021 08:30 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, March 09, 2021 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP, or, the Company), a clinical-stage biotechnology company developing a new class of medicines to treat...
Emerald Health Pharmaceuticals Starts Activities for Initiation of Phase 2 Clinical Study in Multiple Sclerosis
08. März 2021 08:30 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, March 08, 2021 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP or the Company), a clinical-stage biotechnology company developing a new class of medicines to treat...
Emerald Health Pharmaceuticals Demonstrates Potential Disease-Modifying Activity of Novel Product Candidate with Multi-Modal Mechanism of Action in Parkinson’s Disease
09. Februar 2021 09:32 ET
|
Emerald Health Pharmaceuticals
Data published in peer-reviewed journal, Molecular and Cellular Neuroscience, show neuroprotective and neurogenic activity of proprietary product candidate, EHP-102 SAN DIEGO, CA, Feb. 09, 2021 ...
Emerald Health Pharmaceuticals to Open a New Financing Round Under its Regulation A+ Offering
03. Dezember 2020 09:09 ET
|
Emerald Health Pharmaceuticals
New round will open on December 7, 2020 and close on or before March 28, 2021 SAN DIEGO, CA, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage...
Emerald Health Pharmaceuticals Announces Closing Date For its Current Regulation A+ Offering Round
19. Oktober 2020 08:30 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage biotechnology company developing a new class of medicines to treat diseases with unmet...
Emerald Health Pharmaceuticals Begins Enrollment in Phase 2a Study of EHP-101 for the Treatment of Systemic Sclerosis
27. Juli 2020 08:30 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, July 27, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage biotechnology company developing a new class of medicines to treat diseases with unmet...
Emerald Health Pharmaceuticals Renews Regulation A Offering and Provides Mid-Year Corporate Update
20. Juli 2020 13:27 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, July 20, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage biotechnology company developing a new class of medicines to treat diseases with unmet...
Emerald Health Pharmaceuticals Provides Phase 2 Systemic Sclerosis Clinical Trial Update
28. Mai 2020 14:00 ET
|
Emerald Health Pharmaceuticals
Enrollment open in systemic sclerosis study of novel lead product candidate SAN DIEGO, CA, May 28, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage biotechnology...
Emerald Health Pharmaceuticals Initiates Phase 2 Clinical Study in Systemic Sclerosis
31. März 2020 13:13 ET
|
Emerald Health Pharmaceuticals
Novel product candidate, EHP-101, has received Orphan designation and demonstrated a unique multi-pronged mechanism of action related to the treatment of systemic sclerosis SAN DIEGO, CA, March ...
Emerald Health Pharmaceuticals’ Lead Product Candidate Determined Not to be a Controlled Substance in Canada
23. März 2020 10:30 ET
|
Emerald Health Pharmaceuticals
The same previous designation by the US Drug Enforcement Administration alleviates the typical complexities associated with developing controlled substances throughout North America SAN DIEGO,...